
Checkpoint Therapeutics, Inc.

November 29, 2017

Securities and Exchange Commission
Department of Corporation Finance
Washington, D.C. 20549
Attn: Ms. Dorrie Yale

Via: *EDGAR Submission*

Re: **Checkpoint Therapeutics, Inc.**
Registration Statement on Form S-3
Filed November 9, 2017
File No. 333-221493

Ladies and Gentlemen:

Checkpoint Therapeutics, Inc. (the "Company"), hereby requests that the effective date for the Registration Statement referred to above be accelerated so that it will be declared effective at 9:00 a.m. (ET) on Friday, December 1, 2017 or as soon as practicable thereafter, pursuant to Rule 461 of the Securities Act of 1933, as amended.

The Company acknowledges that (i) should the Commission or the staff of the Commission, acting pursuant to delegated authority, declare the filing effective, such declaration does not foreclose the Commission from taking any action with respect to the filing; (ii) the action of the Commission or the staff of the Commission, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and (iii) the Company may not assert the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

Please contact Mark F. McElreath of Alston & Bird LLP with any questions or comments at 212-210-9595. Thank you for your assistance with this filing.

CHECKPOINT THERAPEUTICS, INC.

By: /s/ James Oliviero
James Oliviero
Chief Executive Officer and President

cc: Mark F. McElreath, Esq.
